Analyst Expectations For Incyte’s Future
6 analysts have shared their evaluations of Incyte (NASDAQ:INCY) during the recent three months, expressing a mix of…
Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday’s Risers & Fallers
The Nasdaq 100 index posted its fourth consecutive session in the green on Thursday, closing at 19,576 points and reaching all-time highs.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI.
9 Analysts Have This To Say About Incyte
Incyte (NASDAQ:INCY) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish…
Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What’s Driving Markets Monday?
Wall Street kicked off a data-heavy week on a mixed note as traders await key inflation updates and remarks from Fed Chair Jerome Powell in the coming days.
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones gaining more than 90 points on Monday. Shares of GameStop…
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Across the recent three months, 10 analysts have shared their insights on Incyte (NASDAQ:INCY), expressing a variety of…
Incyte To Acquire Escient And Its Assets For $750M Plus Escient’s Net Cash Remaining At The Close Of The Transaction, Subject To Customary Adjustments
Incyte (NASDAQ:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders, have entered into a